Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been assigned a €95.10 ($113.21) target price by stock analysts at J P Morgan Chase & Co in a report released on Thursday. The firm currently has a “buy” rating on the stock.

Several other equities research analysts have also weighed in on FME. Deutsche Bank AG set a €84.00 ($100.00) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) set a €97.00 ($115.48) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Commerzbank Ag set a €88.00 ($104.76) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Monday, August 7th. Kepler Capital Markets set a €95.00 ($113.10) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Finally, Berenberg Bank set a €92.10 ($109.64) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Hold” and an average price target of €88.39 ($105.22).

Shares of Fresenius Medical Care AG & Co. KGaA (ETR:FME) opened at 81.226 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €70.82 and a 12 month high of €89.07. The stock has a market capitalization of €24.93 billion and a price-to-earnings ratio of 20.945. The firm’s 50 day moving average is €79.13 and its 200 day moving average is €81.58.

TRADEMARK VIOLATION NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/14/j-p-morgan-chase-95-10-price-target-for-fresenius-medical-care-ag-co-kgaa-fme.html.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.